These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. Hasserjian RP Curr Opin Hematol; 2018 Mar; 25(2):120-128. PubMed ID: 29256927 [TBL] [Abstract][Full Text] [Related]
29. [Clinical variability in two cases of systemic mastocytosis]. Bazan-Socha S; Rudzki Z; Maciejewicz J; Witkoś T; Szczeklik A Pol Arch Med Wewn; 2001 Apr; 105(4):311-5. PubMed ID: 11761803 [TBL] [Abstract][Full Text] [Related]
30. [Towards better understanding of hematolymphoid malignancies--based on the WHO-2008 classification: summary]. Tohyama K Rinsho Byori; 2011 May; 59(5):502-3. PubMed ID: 21706866 [TBL] [Abstract][Full Text] [Related]
31. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. Sánchez-Muñoz L; Teodosio C; Morgado JM; Perbellini O; Mayado A; Alvarez-Twose I; Matito A; Jara-Acevedo M; García-Montero AC; Orfao A; Escribano L Immunol Allergy Clin North Am; 2014 May; 34(2):297-313. PubMed ID: 24745675 [TBL] [Abstract][Full Text] [Related]
32. An unexpected association of hematologic malignancies. Athanase N; Frébet E Blood; 2018 Oct; 132(14):1545. PubMed ID: 30287471 [No Abstract] [Full Text] [Related]
33. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Cazzola M Blood; 2016 May; 127(20):2361-4. PubMed ID: 27069255 [No Abstract] [Full Text] [Related]
34. Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms. Kuo FC Surg Pathol Clin; 2016 Sep; 9(3):475-88. PubMed ID: 27523973 [TBL] [Abstract][Full Text] [Related]
35. Bone marrow disorders: recent advances, part I. Introduction. Torlakovic EE; Hyjek E; Butany J Semin Diagn Pathol; 2011 Nov; 28(4):257. PubMed ID: 22195403 [No Abstract] [Full Text] [Related]
36. [Emerging Technologies Support the Molecular Basis of the WHO Classification of Hematopoietic Neoplasms]. Miyachi H Rinsho Byori; 2014 Nov; 62(11):1056-64. PubMed ID: 27509721 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Sánchez-Muñoz L; Alvarez-Twose I; García-Montero AC; Teodosio C; Jara-Acevedo M; Pedreira CE; Matito A; Morgado JM; Sánchez ML; Mollejo M; Gonzalez-de-Olano D; Orfao A; Escribano L Mod Pathol; 2011 Sep; 24(9):1157-68. PubMed ID: 21552214 [TBL] [Abstract][Full Text] [Related]
38. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Escribano L; Díaz-Agustín B; Bellas C; Navalón R; Nuñez R; Sperr WR; Schernthaner GH; Valent P; Orfao A Leuk Res; 2001 Jul; 25(7):563-70. PubMed ID: 11377681 [TBL] [Abstract][Full Text] [Related]
39. Immunophenotyping of acute leukemia: utility of CD45 for blast cell identification. Vial JP; Lacombe F Methods Cell Biol; 2001; 64():343-58. PubMed ID: 11070847 [No Abstract] [Full Text] [Related]
40. [Mastocytosis: when should it be considered?]. Comte-Perret S; Bart PA; Spertini F; Leimgruber A Rev Med Suisse; 2009 Apr; 5(199):837-42. PubMed ID: 19441750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]